Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Elevated MIBG Activity at the Site of Erythema of Unknown Etiology.

Xie P, Monaghan R, Edwards K, Shao F, Zhuang H.

Clin Nucl Med. 2017 Mar;42(3):227-230. doi: 10.1097/RLU.0000000000001494.

PMID:
27997425
2.

Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.

Rutgers M, Buitenhuis CK, Hoefnagel CA, Voûte PA, Smets LA.

Int J Cancer. 2000 Aug 1;87(3):412-22.

3.

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

Modak S, Zanzonico P, Carrasquillo JA, Kushner BH, Kramer K, Cheung NK, Larson SM, Pandit-Taskar N.

J Nucl Med. 2016 Feb;57(2):231-7. doi: 10.2967/jnumed.115.161752. Epub 2016 Jan 7.

4.

Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine.

Roa WH, Miller GG, McEwan AJ, McQuarrie SA, Tse J, Wu J, Wiebe LI.

Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):425-32.

PMID:
9607361
5.

Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

Willegaignon J, Crema KP, Oliveira NC, Pelissoni RA, Coura-Filho GB, Sapienza MT, Buchpiguel CA.

Clin Nucl Med. 2018 Aug;43(8):572-578. doi: 10.1097/RLU.0000000000002158.

PMID:
29916922
6.

[Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].

Défachelles AS, Cougnenc O, Carpentier P.

Bull Cancer. 2011 May;98(5):559-69. doi: 10.1684/bdc.2011.1353. Review. French.

7.

Diagnostic and therapeutic use of MIBG in pheochromocytoma and paraganglioma.

Aktolun C, Castellani MR, Bombardieri E.

Q J Nucl Med Mol Imaging. 2013 Jun;57(2):109-11. No abstract available.

PMID:
23822987
8.

MIBG in Neuroblastoma Diagnostic Imaging and Therapy.

Sharp SE, Trout AT, Weiss BD, Gelfand MJ.

Radiographics. 2016 Jan-Feb;36(1):258-78. doi: 10.1148/rg.2016150099. Review.

PMID:
26761540
9.

Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.

Mazloom A, Louis CU, Nuchtern J, Kim E, Russell H, Allen-Rhoades W, Krance R, Paulino AC.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):858-62. doi: 10.1016/j.ijrobp.2014.07.019. Epub 2014 Sep 20.

10.

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.

Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V, Troncone L, Mastrangelo R.

Br J Cancer. 2001 Feb;84(4):460-4.

11.

Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.

Kinuya S, Li XF, Yokoyama K, Mori H, Shiba K, Watanabe N, Shuke N, Bunko H, Michigishi T, Tonami N.

Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1246-50. Epub 2003 Jun 17.

PMID:
12811531
12.

Abnormal MIBG uptake in a neuroblastoma patient with right upper lobe atelectasis.

Acharya J, Chang PT, Gerard P.

Pediatr Radiol. 2012 Oct;42(10):1259-62. doi: 10.1007/s00247-012-2413-3. Epub 2012 May 22.

PMID:
22618629
13.

Asymmetric thoracic metaiodobenzylguanidine (MIBG) activity due to prior radiation therapy.

Bai X, Yang H, Zhuang H.

Clin Nucl Med. 2015 Jun;40(6):e338-40. doi: 10.1097/RLU.0000000000000760.

PMID:
25742240
14.

I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma.

Yang J, Codreanu I, Servaes S, Zhuang H.

Nucl Med Commun. 2012 Nov;33(11):1134-7.

PMID:
22825037
15.

Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.

Barrett JA, Joyal JL, Hillier SM, Maresca KP, Femia FJ, Kronauge JF, Boyd M, Mairs RJ, Babich JW.

Cancer Biother Radiopharm. 2010 Jun;25(3):299-308. doi: 10.1089/cbr.2009.0695.

16.

Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.

Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD.

J Nucl Med. 2009 Sep;50(9):1518-24. doi: 10.2967/jnumed.109.064469.

17.

Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma.

Dahllöf G, Borgström P, Lundell G, Jacobsson H, Kogner P.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Oct;92(4):420-3.

PMID:
11598577
18.

A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.

Hoefnagel CA, Rutgers M, Buitenhuis CK, Smets LA, de Kraker J, Meli M, Carrel F, Amstutz H, Schubiger PA, Novak-Hofer I.

Eur J Nucl Med. 2001 Mar;28(3):359-68.

PMID:
11315605
19.

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

DuBois SG, Matthay KK.

Nucl Med Biol. 2008 Aug;35 Suppl 1:S35-48. doi: 10.1016/j.nucmedbio.2008.05.002. Review.

20.

Supplemental Content

Support Center